-
Something wrong with this record ?
Effect of substituents at the C3 ́, C3 ́N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells
P. Daniel, K. Balušíková, J. Truksa, J. Černý, M. Jaček, M. Jelínek, MJV. Mulenga, K. Voráčová, L. Chen, L. Wei, Y. Sun, I. Ojima, J. Kovář
Language English Country United States
Document type Journal Article
Grant support
R01 CA103314
NCI NIH HHS - United States
- MeSH
- Benzoates pharmacology chemistry MeSH
- Drug Resistance, Neoplasm * drug effects MeSH
- Humans MeSH
- MCF-7 Cells MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms drug therapy pathology MeSH
- Ovarian Neoplasms drug therapy pathology MeSH
- ATP Binding Cassette Transporter, Subfamily B * metabolism genetics MeSH
- Paclitaxel pharmacology MeSH
- Antineoplastic Agents pharmacology chemistry MeSH
- Taxoids pharmacology chemistry MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
We tested the effect of substituents at the (1) C3 ́, C3 ́N, (2) C10, and (3) C2-meta-benzoate positions of taxane derivatives on their activity against sensitive versus counterpart paclitaxel-resistant breast (MCF-7) and ovarian (SK-OV-3) cancer cells. We found that (1) non-aromatic groups at both C3 ́ and C3 ́N positions, when compared with phenyl groups at the same positions of a taxane derivative, significantly reduced the resistance of ABCB1 expressing MCF-7/PacR and SK-OV-3/PacR cancer cells. This is, at least in the case of the SB-T-1216 series, accompanied by an ineffective decrease of intracellular levels in MCF-7/PacR cells. The low binding affinity of SB-T-1216 in the ABCB1 binding cavity can elucidate these effects. (2) Cyclopropanecarbonyl group at the C10 position, when compared with the H atom, seems to increase the potency and capability of the derivative in overcoming paclitaxel resistance in both models. (3) Derivatives with fluorine and methyl substituents at the C2-meta-benzoate position were variously potent against sensitive and resistant cancer cells. All C2 derivatives were less capable of overcoming acquired resistance to paclitaxel in vitro than non-substituted analogs. Notably, fluorine derivatives SB-T-121205 and 121,206 were more potent against sensitive and resistant SK-OV-3 cells, and derivatives SB-T-121405 and 121,406 were more potent against sensitive and resistant MCF-7 cells. (4) The various structure-activity relationships of SB-T derivatives observed in two cell line models known to express ABCB1 favor their complex interaction not based solely on ABCB1.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019538
- 003
- CZ-PrNML
- 005
- 20241024110807.0
- 007
- ta
- 008
- 241015e20240612xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2024.116993 $2 doi
- 035 __
- $a (PubMed)38870637
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Daniel, Petr $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: petr.daniel@lf3.cuni.cz
- 245 10
- $a Effect of substituents at the C3 ́, C3 ́N, C10 and C2-meta-benzoate positions of taxane derivatives on their activity against resistant cancer cells / $c P. Daniel, K. Balušíková, J. Truksa, J. Černý, M. Jaček, M. Jelínek, MJV. Mulenga, K. Voráčová, L. Chen, L. Wei, Y. Sun, I. Ojima, J. Kovář
- 520 9_
- $a We tested the effect of substituents at the (1) C3 ́, C3 ́N, (2) C10, and (3) C2-meta-benzoate positions of taxane derivatives on their activity against sensitive versus counterpart paclitaxel-resistant breast (MCF-7) and ovarian (SK-OV-3) cancer cells. We found that (1) non-aromatic groups at both C3 ́ and C3 ́N positions, when compared with phenyl groups at the same positions of a taxane derivative, significantly reduced the resistance of ABCB1 expressing MCF-7/PacR and SK-OV-3/PacR cancer cells. This is, at least in the case of the SB-T-1216 series, accompanied by an ineffective decrease of intracellular levels in MCF-7/PacR cells. The low binding affinity of SB-T-1216 in the ABCB1 binding cavity can elucidate these effects. (2) Cyclopropanecarbonyl group at the C10 position, when compared with the H atom, seems to increase the potency and capability of the derivative in overcoming paclitaxel resistance in both models. (3) Derivatives with fluorine and methyl substituents at the C2-meta-benzoate position were variously potent against sensitive and resistant cancer cells. All C2 derivatives were less capable of overcoming acquired resistance to paclitaxel in vitro than non-substituted analogs. Notably, fluorine derivatives SB-T-121205 and 121,206 were more potent against sensitive and resistant SK-OV-3 cells, and derivatives SB-T-121405 and 121,406 were more potent against sensitive and resistant MCF-7 cells. (4) The various structure-activity relationships of SB-T derivatives observed in two cell line models known to express ABCB1 favor their complex interaction not based solely on ABCB1.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 12
- $a P-glykoproteiny $x metabolismus $x genetika $7 D018435
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a taxoidy $x farmakologie $x chemie $7 D043823
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a paclitaxel $x farmakologie $7 D017239
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nádory prsu $x farmakoterapie $x patologie $7 D001943
- 650 _2
- $a protinádorové látky $x farmakologie $x chemie $7 D000970
- 650 _2
- $a benzoáty $x farmakologie $x chemie $7 D001565
- 650 _2
- $a nádory vaječníků $x farmakoterapie $x patologie $7 D010051
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Balušíková, Kamila $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Truksa, Jaroslav $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic; Laboratory of Tumor Resistance, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Centre, Vestec, Czech Republic
- 700 1_
- $a Černý, Jiří $u Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Centre, Vestec, Czech Republic
- 700 1_
- $a Jaček, Martin $u Department of Hygiene, Epidemiology and Preventive Medicine, Third Faculty of Medicine, Charles Univesity, Prague, Czech Republic
- 700 1_
- $a Jelínek, Michael $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Mulenga, Mutale Jane Vobruba $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Voráčová, Kateřina $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Chen, Lei $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
- 700 1_
- $a Wei, Longfei $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
- 700 1_
- $a Sun, Yi $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
- 700 1_
- $a Ojima, Iwao $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA
- 700 1_
- $a Kovář, Jan $u Division of Cell and Molecular Biology, Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: jan.kovar@lf3.cuni.cz
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 489 (20240612), s. 116993
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38870637 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110801 $b ABA008
- 999 __
- $a ok $b bmc $g 2202021 $s 1231511
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 489 $c - $d 116993 $e 20240612 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- GRA __
- $a R01 CA103314 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20241015